Allogene Overland Biopharm has completed construction of a cGMP manufacturing facility in Shanghai to support the development of AlloCAR T™ products in Asia.

[ad_1]

China Taiwan The GMP site is designed to enable potential clinical and commercial production of AlloCAR T™ products for patients in South Korea and Singapore.

South SAN FRANCISCO, Calif. October 31st 2022 (GLOBE NEWSWIRE) — Overland Pharmaceuticals and Allogene Therapeutics Inc. (Nasdaq: ALLO), developed by Allogene Overland Biopharm (Allogene Overland); joint ventures; China, a company that develops allogeneic CAR T (AlloCAR T™) products for cancer. Today announced the completion of construction of a state-of-the-art AlloCAR T manufacturing facility in Shanghai.

Shuyuan Yao, CEO of Allogene Overland, said, “This is an extraordinary milestone. “Our state-of-the-art facility will enable us to accelerate the development of licensed AlloCAR T products from the world’s leading allogeneic CAR T company and, ultimately, play an important role in bringing cell therapy to the shelf in China and other Asia Pacific markets.”

The 68,000 square foot GMP facility utilizes a flexible modular design suitable for all types of cell therapy production. This scalable approach enables the production of multiple AlloCAR T products simultaneously, aiming to meet the needs of cancer patients in Asia.

“We recognize that China, with its large, diverse and geographically dispersed population, faces great barriers to adoption. This new manufacturing facility in Shanghai will not only improve our joint venture’s capabilities and pave the way to serve the number of patients who will benefit from allogeneic CAR T therapies, but will also provide an opportunity to develop new indications and new targets. said Alison Moore, Allogene’s chief technology officer and member of Allogene Overland Biopharm’s board of directors.

Allogene Overland Biopharm’s pipeline is BCMA in licensed territories; CD70, development of specific allogeneic candidates targeting FLT3 and DLL3; Focused on manufacturing and commercialization.

About Allogene Overland Biopharm
Allogene Overland Biopharm, created by Overland Pharmaceuticals and Allogene Therapeutics, aims to accelerate the global development of AlloCAR T™ therapies for patients with malignancies and tumors in China and other Asia Pacific regions.

About Overland Pharmaceuticals
Overland Pharmaceuticals is building a fully integrated biopharmaceutical company with the mission of bringing innovative medicines to patients in Asia and around the world. its resources; By leveraging global network and local expertise across the biopharma ecosystem in Asia; Overland is establishing a diverse portfolio of therapeutic candidates in a select number of carefully selected therapeutic areas. Through these partnerships, Overland will advance the development and commercialization of the most promising advances in medicine. www.overlandpharma.com.

About Allogene Therapeutics
Headquartered in South San Francisco, Allogene Therapeutics is a clinical-stage biotechnology company developing allogeneic chimeric antigen receptor T cell (AlloCAR T™) products for cancer. Led by a management team with significant experience in cell therapy, Allogene provides on-demand, on-demand cell therapy that is readily available. Allogene is developing a pipeline of “off-the-shelf” CAR T cell candidates with the goal of providing cell therapy that is more reliable and readily available on a larger scale. More patients. For more information, Please visit www.allogene.com and follow @AllogeneTx on Twitter and LinkedIn.

Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The statement may in some cases use terms such as “estimates”, “beliefs”, “potential”. “proposes,” “continues,” “estimates,” “anticipates,” “anticipates,” “plans,” “intends,” “may,” “could,” “could,” “will,” “should” or other words; Uncertainties of future events or results are expressed to identify these expectations. Objectives; Beliefs predictions; expectations Analyzes or statements regarding current expectations include: Allogene Overland’s ability to manufacture AlloCAR T product candidates, including the safety and feasibility of raw materials; development or commercial production capability; the ability to obtain regulatory clearance for the manufacturing process for AlloCAR T product candidates and the initiation of any clinical trials in the licensed territories; and potential benefits of AlloCAR T. Various factors could cause differences between Allogene’s expectations and actual results as detailed in Allogene’s filings, including but not limited to the Form 8-K filed with the Securities and Exchange Commission (SEC) on September 21, 2022; 2022, Form 8-K filed on October 6 and Form 10-Q for the quarter ended June 30, 2022. Any forward-looking statements contained in this press release speak only as of the date of this press release. Allogene may provide new information after the date of this press release. It assumes no obligation to update any forward-looking statements, whether as a result of future events or otherwise.

AlloCAR T™ is a trademark of Allogene Therapeutics, Inc.

Allogene Media/Investor Contact:
Christine Cassiano
Chief Communications Officer
(714) 552-0326
[email protected]

Jessica Bernstein
Senior Manager Corporate and internal communications
(310) 781-0577
[email protected]